Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions

Organovo (NASDAQ:ONVO) announced that its wholly-owned subsidiary, Samsara Sciences, a provider of highly specialized human liver cells, entered a non-exclusive global supply agreement with Lonza Bioscience Solutions.  Under the terms of the agreement, Lonza will market human cell products from Samsara for further distribution to its customers.

As quoted in the press release:

“We’re incredibly pleased to begin this partnership with Lonza, which allows us to tap into their outstanding global sales and marketing capabilities and expand the reach of our human cell products,” said Dr. Sharon Presnell, president, Samsara and chief scientific officer, Organovo.  “This agreement, which represents Samsara’s single largest contract to date, continues to establish Samsara as an emerging leader in the production and delivery of specialty human liver cells for use by biopharma clients in their research programs.  Samsara has more than doubled its sales over the last year, and we expect that growing demand for our library of well-characterized healthy and disease-origin cells will continue to provide attractive revenue opportunities for our business.”

Click here to read the full press release.